Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.
BMJ. 2008; 336:(7653)1121-1123
https://doi.org/10.1136/bmj.39548.738368.be
Bradford L, Ringshaw J, Wedderburn CJ Brain structure of South African HEU children exposed to dolutegravir versus efavirenz. Top Antivir Med.. 2024; 32:(1)
Carstens RP, Kapoor Y, Vargo R Single dose administration of MK-8527, a novel nRTTI, in adults with HIV-1. Top Antivir Med.. 2024; 32:(1)
Colson A, Crofoot G, Ruane PJ Efficacy and safety of weekly islatravir plus lenacapavir in PWH at 24 weeks: A phase II study. Top Antivir Med.. 2024; 32:(1)
Erlandson KM, Umbleja T, Ribaudo HJ Pitavastatin has no effect on long-term, objective physical function in REPRIEVE. Top Antivir Med.. 2024; 32:(1)
Feinstein MJ, Hsue PY, Benjamin LA Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association.
Circulation.. 2019; 140:(2)e98-e124
https://doi.org/10.1161/cir.0000000000000695
Fichtenbaum CJ, Berhe M, Bordon J Antiviral activity, safety, and pharmacokinetics of GS-1720: a novel weekly oral InSTI. Top Antivir Med.. 2024; 32:(1)
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet.. 2024; 403:(10440)2100-2132
https://doi.org/10.1016/s0140-6736(24)00367-2
Griffiths G, Fitzgerald R, Jaki T AGILE-ACCORD: A randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
Trials.. 2020; 21:(1)
https://doi.org/10.1186/s13063-020-04473-1
Hickey M, Owaraganise A, Ogachi S Community health worker-facilitated telehealth for severe hypertension care in Kenya and Uganda. Top Antivir Med.. 2024a; 32:(1)
Hickey M, Grochowski J, Mayorga-Munoz F 24-week viral suppression in patients starting long-acting CAB/RPV without HIV viral suppression. Top Antivir Med.. 2024b; 32:(1)
Kityo CM, Mambule IK, Sokhela S Randomized trial of cabotegravir and rilpivirine long-acting in Africa (CARES): Week 48 results. Top Antivir Med. 2024; 32:(1)
Kolossváry M, Schnittman SR, Zanni M Pitavastatin reduces non-calcified plaque via pro-collagen PCOLCE independently of LDL in REPRIEVE. Top Antivir Med.. 2024; 32:(1)
Longenecker CT, Jones KA, Hileman CO A nurse-led strategy improves blood pressure and cholesterol in people with HIV: the EXTRA-CVD trial. Top Antivir Med. 2024a; 32:(1)
Malaba TR, Nakatudde I, Kintu K 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Lancet HIV.. 2022; 9:(8)e534-e543
https://doi.org/10.1016/S2352-3018(22)00173-4
Malaba TR, Orrell C, Else L ART adherence and elevated viral load in pregnant & postpartum women initiating DTG versus EFV. Top Antivir Med.. 2024a; 32:(1)
Malaba TR, Nassiwa S, He N DTG versus EFV initiation in pregnancy is not associated with postpartum blood pressure. Top Antivir Med.. 2024b; 32:(1)
Rana AI, Bao Y, Zheng L Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359 [LATITUDE]. Top Antivir Med.. 2024; 32:(1)
Sax PE, Thompson MA, Saag MS IAS-USA Treatment Guidelines Panel.
Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel. JAMA.. 2024; 331:(12)1060-1061
https://doi.org/10.1001/jama.2024.2985
van der Wekken-Pas L, Nassiwa S, Malaba T Dolutegravir versus efavirenz: Depression, anxiety, and sleep disorders in pregnancy and postpartum. Top Antivir Med.. 2024a; 32:(1)
van der Wekken-Pas L, Nassiwa S, Malaba T Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
AIDS.. 2024b; 38:(7)975-981
https://doi.org/10.1097/QAD.0000000000003852
Waters L, Winston A, Reeves I BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
HIV Med. 2022; 23:(Suppl 5)3-115
https://doi.org/10.1111/hiv.13446
Yan LD, Rouzier V, Sufra R Treatment of prehypertension in people living with HIV: a randomized controlled trial. Top Antivir Med.. 2024; 32:(1)
